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STATE OF THE ART: CONCISE REVIEW
Image-Guided Radiation Therapy for Non-small
Cell Lung Cancer
Joe Y. Chang, MD, PhD,* Lei Dong, PhD,† Helen Liu, PhD,† George Starkschall, PhD,†
Peter Balter, PhD,† Radhe Mohan, PhD,† Zhongxing Liao, MD,* James D. Cox, MD,*
and Ritsuko Komaki, MD*
Recent developments in image-guided radiotherapy are ushering in
a new era of radiotherapy for lung cancer. Positron emission tomog-
raphy/computed tomography (PET/CT) has been shown to improve
targeting accuracy in 25 to 50% of cases, and four-dimensional CT
scanning helps to individualize radiotherapy by accounting for
tumor motion. Daily on-board imaging reduces treatment set-up
uncertainty and provides information about daily organ motion and
variations in anatomy. Image-guided intensity-modulated radiother-
apy may allow for the escalation of radiotherapy dose with no
increase in toxicity. More importantly, treatment adaptations based
on anatomic changes during the course of radiotherapy and dose
painting within involved lesions using functional imaging such as
PET may further improve clinical outcomes of lung cancer patients
and potentially lead to new clinical trials. Image-guided stereotactic
radiotherapy can achieve local control rates exceeding 90% through
the use of focused, hypofractionated, highly biologically effective
doses. These novel approaches were considered experimental just a
few years ago, but accumulating evidence of their potential for
significantly improving clinical outcomes is leading to their inclu-
sion in standard treatments for lung cancer at major cancer centers.
In this review article, we focus on novel image-guided radiotherapy
approaches, particularly PET/CT and four-dimensional CT-based
radiotherapy planning and on-board image-guided delivery, stereo-
tactic radiotherapy, and intensity-modulated radiotherapy for mobile
nonsmall cell lung cancer.
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cancer, target volume delineation, 4-D CT, PET/CT, stereotactic
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Radiation therapy plays a crucial role in the management oflung cancer. However, with two-dimensional (2-D) radio-
therapy planning, the local control was poor and dose escalation
was associated with increased toxicity, particularly when con-
current chemotherapy was given.1 Three-dimensional (3-D)
conformal radiotherapy (3-D CRT) might improve local control
and possibly survival compared with 2-D therapy in stage I
nonsmall cell lung cancer (NSCLC).2 In addition, dose-escala-
tion phase I/II clinical studies have shown promising clinical
outcomes in stage III NSCLC, with improvements in survival
and toxicity, with the use of 3-D CRT, although a phase III study
is needed to confirm the results.3,4
The three main reasons for local failure after radiotherapy
are (1) geographic misses due to inadequacy of imaging tools for
staging and radiotherapy planning; (2) geographic misses due to
respiratory tumor motion during radiation delivery; and (3)
inadequate radiation dose because of the potential for significant
toxicity. Image-guided radiotherapy (IGRT), particularly radio-
therapy planning based on positron emission tomography/com-
puted tomography (PET/CT), consideration of individualized
tumor motion with four-dimensional (4-D) CT, and on-board
imaging-guided adapted radiotherapy during the course of treat-
ment may allow more accurate tumor targeting and reduce side
effects. IGRT with radiation dose escalation or acceleration
could significantly improve clinical outcomes for patients with
lung cancer. For example, image-guided stereotactic body ra-
diotherapy (SBRT) has been shown in phase II clinical trials to
improve local control and survival in early-stage NSCLC com-
pared with historical data,5–9 and intensity-modulated radiother-
apy (IMRT) may be better tolerated10,11 than 3-D CRT.
As information about IGRT for lung cancer continues
to emerge, “standard” radiotherapy approaches for patients
with NSCLC are evolving. Guidelines and step-by-step tech-
niques for the use of IGRT in mobile lung cancers are needed
to implement IGRT into daily clinical practice. In this review,
we discuss the role of radiotherapy in NSCLC and our
recommendations/suggestions and techniques for IGRT de-
sign and adapted radiotherapy to take intrafraction and inter-
fraction tumor motion into consideration.
IMAGE-GUIDED TARGET VOLUME
DELINEATION
Guidelines from the International Commission on Ra-
diation Units Report No. 5012 for defining targets have been
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applied to the treatment of lung cancer. The gross tumor
volume (GTV) is defined as tumor that is visible by any
imaging modality (the primary tumor) along with any grossly
involved lymph nodes. The clinical target volume (CTV) is
the anatomically defined area (e.g., the hilar or mediastinal
lymph nodes or a margin around the grossly visible disease)
believed to harbor microscopic disease. The planning target
volume (PTV) includes a margin around the CTV to account
for physiologic organ motion during treatment and day-to-
day set-up errors in fractionated therapy. The target volumes
are defined by image-guided procedures as follows.
Gross Tumor Volume
The pulmonary extent of lung tumors should be
delineated on pulmonary windows and level settings in CT
images, and the mediastinal extent of tumors should be
delineated using mediastinal windows and level settings.
In general, a lymph node larger than 1 cm in its shortest
dimension on CT is considered positive, because the risk
of involvement is more than 15%.13 Functional imaging
such as fluorodeoxyglucose (FDG)-PET is quite important
for disease staging14 and radiation treatment volume delinea-
tion15,16 in NSCLC, particularly in stage III disease. In par-
ticular, FDG-PET can help to categorize suspected mediasti-
nal and hilar lymph node adenopathy and distinguish benign
collapsed lung tissue from tumor (Figure 1A, B).
There are still many unresolved questions and con-
troversies in FDG-PET-guided radiotherapy planning.17
Several approaches have been suggested for defining ma-
lignant GTV using FDG-PET: (1) visual interpretation of
the FDG-PET image and tumor contours18; (2) using a
percentage (e.g., 40 or 50%) of the maximal uptake as the
threshold for radiotherapy target volume delineation15; and
(3) using a threshold for image segmentation, although the
optimal value has not been well defined. Currently, a
standard uptake value (SUV) equal to or higher than 2.5 is
suggested as a threshold.19 However, the SUV is deter-
mined not only by the presence of cancer but also by the
size of the lesion, presence of inflammation, timing of
imaging after injection of 18F-FDG, blood glucose level,
etc. FDG-PET scanning usually can only detect cancer le-
sions larger than 5 to 10 mm. For smaller lesions, clinical
judgment should be applied. Inflammation can cause false-
positive findings on FDG-PET scans, and biopsy is recom-
mended in the event of questionable findings (Figure 1C).
Pre- and posttreatment SUVs of FDG-PET were
found to be predictive of survival in NSCLC.20,21 Recent
clinical data have also shown that in NSCLC treated with
standard concurrent chemoradiotherapy, an SUV higher
than 13.8 was associated with a local recurrence rate of
65.5% compared with a rate of 25% in lesions with an
SUV 13.8.22 In theory, with specific radioactive tracers,
functional imaging techniques such as PET can visualize
biologic pathways with particular significance for tumor
response to therapy, such as higher SUVs, hypoxia, and
altered gene expression. These subvolumes of the tumor can
serve as a “target in a target” and allow for dose painting
using IMRT.23,24
Because PET scans are acquired over multiple breath-
ing cycles, as opposed to the “snapshots” acquired with CT
imaging, significant image mismatch can occur using con-
ventional PET/CT if the tumor moves more than 5 mm during
the breathing cycle. 4-D CT-based attenuation correction of
PET or gated PET is recommended if the tumor moves
significantly.25
Clinical Tumor Volume
A radiographic–histopathologic study of lung paren-
chymal disease26 demonstrated that GTV-to-CTV expansions
of 6 mm for squamous cancers and 8 mm for adenocarcino-
mas are required to cover the gross tumor and microscopic
disease with 95% accuracy. Expansions for other histologic
tumor types have not been determined, but a conservative
approach would be to use 8 mm. An appropriate CTV for
mediastinal involvement has not been rigorously determined.
An abstract presented at the 2006 meeting of the American
Society for Therapeutic Radiology and Oncology indicated
that the maximal microscopic extension of involved lymph
nodes is between 0.5 and 8.9 mm (average, 3.2 mm).27 Based
on this information, we use 8-mm expansions around in-
volved nodes (those showing gross involvement or positive
findings on FDG-PET). Obviously, these expansions should
not necessarily be applied uniformly along all axes and
should always be individualized on the basis of the location
of the primary tumor and involved lymph node. In the
absence of radiographic proof of invasion, the CTV of the
primary lesion should not extend into the chest wall or
mediastinum. CTV expansions for lymph node disease
FIGURE 1. Positron emission tomography–computed to-
mography (PET-CT)-guided target volume delineation. A, A
PET-CT image indicates right hilar lymph node involvement
that was not clearly evident on the CT image alone. B, A
PET/CT image differentiates gross tumor from collapsed lung
tissue. C, False-positive PET-CT scans can be caused by in-
flammation caused by infection or postradiation pneumoni-
tis. The right upper lobe lesion was squamous cell carcino-
ma; however, the left upper lobe lesion was shown on
biopsy to be inflammation.
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should not extend into the major airways or the lung, chest
wall, or vertebral body without evidence of invasion on CT or
magnetic resonance imaging.
Restricting the target volume to gross disease or omit-
ting elective nodal irradiation for the treatment of NSCLC
remains the subject of debate. Previous studies using CT-
based planning reported low rates of isolated out-of-field recur-
rences, in the range of 0 to 6.4%, suggesting that this approach
is reasonable.28–31 A multicenter study (RTOG 9311) also
showed that the elective nodal irradiation failure rate was
8%.31 A recent study22 showed that limiting the target volume
to PET-positive disease was associated with a similar low rate of
isolated out-of-field failure (5.7%). However, the low rate of
isolated out-of-field failures is in part a consequence of high
rates of in-field failures. As the risk of in-field failures decreases
with increasing dose or the use of new radiosensitizers, the rates
of elective nodal failures may increase. Currently, it seems
reasonable to omit elective nodal irradiation to limit toxicity, but
this may need to be reevaluated when local control improves.
Planning Target Volume
The PTV is defined as the CTV plus a margin to account
for daily set-up error and target motion (Figure 2). Our unpub-
lished data show that when patients are immobilized with a
Vac-Loc bag and T-bar, an expansion of 7 mm along all axes
accounts for 95% of the day-to-day uncertainty in set-up. Set-up
uncertainty probably is a function of both the technique and the
institutional practices and should be measured for each individ-
ual undergoing each type of technique. In our institution, use of
a daily kV image can reduce the set-up uncertainty to 5 mm. Use
of a daily on-board image such as with CT on-rails or cone-beam
CT before each radiotherapy fraction can reduce the day-to-day
setup uncertainty to 3 mm (unpublished data). Consideration of
tumor motion is critical for lung cancer radiotherapy and, thus,
is discussed at some length in the following paragraphs.
Tumor Motion Consideration
A major obstacle to radiotherapy target delineation has
been respiration-induced target motion (also known as in-
trafractional tumor motion), which can add considerable
geometrical uncertainty to the radiation treatment. Such mo-
tion requires enlargement of the treatment field portals to
cover the movement of the tumor during treatment. The
development of 4-D CT with multislice detectors and faster
imaging reconstruction has facilitated the ability to obtain
images while patients breathe and to assess organ motion.32
4-D CT involves acquiring over-sampled CT information and
correlating these data with information about the respiratory
cycle (Figure 2A).
Tumor motion is best assessed individually for each
patient. For patients in whom the tumor moves 5 mm,
simply expanding the PTV margin is adequate. However, for
patients with substantial tumor motion, particularly more than
1 cm, an individualized tumor motion margin should be
considered. A 4-D CT study33 showed that more than 50% of
tumors moved more than 5 mm during treatment, and 10.8%
moved more than 1 cm (possibly as much as 3–4 cm), partic-
ularly lesions close to the diaphragm. To address tumor motion,
the International Commission on Radiation Units Report 62 in
1999 introduced the concept of internal target volume (ITV),
which combines the ventilatory or other intrafractional target
motion margin and the CTV (Figure 2B).
A 4-D CT simulation is desirable for evaluating tumor
motion and for providing an individualized assessment of the
target volume and margin. Patients should be evaluated for
regularity of breathing, responsiveness to feedback guidance,
breath-holding capability, and suitability for implantation of
fiducial markers. The findings of this evaluation should then
be used to select one of the following treatment-delivery
techniques: free breath, breath-hold, ventilatory gating, or
motion tracking.
Free Breath Approach
4-D CT-Based ITV
When 4-D CT is available for treatment planning, we
propose the use of a new concept called internal gross tumor
volume (IGTV; Figure 2C), which is the envelope of the
GTV throughout its motion during respiration. Delineating
the IGTV from 4-D CT images involves outlining the tumor
volume on the expiratory phase of the 4-D images and register-
ing the outline on other phases of the images to create a union of
target contours enclosing all possible positions of the target.
Another method is to create an image of maximum intensity
projection by combining data from the multiple CT data sets
with data from the whole-breath cycle and modify tumor volume
by visual verification of the target volume throughout 10 breath-
ing phases (10 phases were chosen based on the practical
signal-to-noise ratio, reconstruction time, and radiation dose
exposure, see Ref. 34). In this case, the ITV should consist of the
IGTV plus a margin to account for microscopic disease (8 mm).
Even with 4-D CT, the free-breathing simulation is only a
snapshot and a single stochastic sampling of the patient’s breath-
ing. Attention should be paid to irregular breathing and varia-
tions in the patient’s breathing pattern over the course of each
treatment session and the entire treatment course and to the
effects of these irregularities on the ITV margin (see late dis-
cussion; Refs. 35 and 36). If 4-D CT is not available, alternative
approaches such as those that follow should be used to account
for tumor motion.
ITV Based on Breath-Hold Spiral CT Simulation
If a patient is unable to hold his breath during the
delivery of radiation, an ITV can be developed based on
breath-hold spiral CT images that require the patient to hold
his breath once during the simulation at the end of expiration
and once at the end of inspiration but not during treatment
delivery. In this procedure, images are acquired through the
use of a standard extended temporal thoracic CT protocol. In
this protocol, patients are asked to breathe normally, and the
extended temporal CT images are acquired at the beginning
of the simulation; the isocenter is then set. Subsequently,
images are obtained by using a fast CT simulation protocol
while at 100% tidal volume (end of inspiration) and 0% tidal
volume (end of expiration). The traces from the real-time
position management system should be recorded. Separate
GTVs and CTVs should be delineated by a physician both at
the end of expiration CT image set and at the end of
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FIGURE 2. A, 4-D CT image to take motion into consideration. The CT images are acquired with the patient in a single
couch position for a period of time slightly longer than a single respiratory cycle; then the couch is indexed a distance equal
to the detector width. Images are fused based on the phase of the respiratory cycle and 4-D images generated. B, Graphic
representation of the International Commission on Radiation Units (ICRU) definitions of gross tumor volume (GTV), clinical
tumor volume (CTV), internal target volume (ITV), and planning target volume (PTV). Arrows indicate CTV motion. C, Graphic
representation of tumor motion during the breathing cycle based on 4-D CT images. IGTV, internal gross tumor volume; T50,
end of expiration (the ideal phase for respiratory-gated therapy); T0, end of inspiration (the ideal phase for breath-hold radio-
therapy). Breath should be evaluated and tumor motion considered by using 4-D CT. If the tumor moves more than 1 cm
and the patient can tolerate the breath-hold technique, the tumor should be treated with active breath-hold radiotherapy at
the end of inspiration (T0 phase). If the patient cannot tolerate breath-hold but can breathe regularly, the tumor should be
treated with gated radiotherapy at the end of expiration (T50). However, if the patient can neither hold their breath nor
breathe regularly, an ITV approach should be used, preferably the approach that uses maximal intensity projection image cov-
erage of the envelope of the tumor motion path.
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inspiration image set (Figure 2C). An ITV is then generated
by combining the two CTVs on the extended temporal CT
scan to form an ITV that includes the entire path of the CTV
as it moves from inspiration to expiration. A 3-mm margin
should be added to account for uncertainties of tumor motion
and image registration. Normal tissues should be contoured in
the extended temporal CT images as well. The IVT should be
superimposed on the slow CT images, which will serve as the
basis for treatment planning.
Breath-Hold Approach
The breath-hold treatment-delivery method is the most
accurate for patients who are able to comply. Two techniques
are in common use for breath-holding at reproducible points
in the respiratory cycle—active breathing control and deep
inspiration breath-hold.37–38 The radiation beam is initiated
while the breath is being held. With these techniques, respi-
ratory tumor excursion is limited to fixed volumes and dia-
phragm excursion is limited to about 5 mm instead of 10 to
15 mm. These techniques require cooperative patients who
are able to hold their breaths for at least 15 seconds. Unfor-
tunately, patients with poor pulmonary function (those who
would most benefit from minimizing the irradiated lung
volume) are the least able to comply with breath-hold tech-
niques. Their breathing also tends to be irregular during the
delivery of radiation.
Ventilatory-Gated Approach
When available, the ventilatory gating method39 can be
used to treat patients who cannot hold their breaths for the
breath-hold treatment delivery but can breathe regularly and
reproducibly. Several commercially available systems can be
used with this technique, in which an externally placed
fiducial marker is tracked as the patient breathes. The beam
can be triggered at a chosen point in the ventilatory cycle,
typically at end-expiration because it is the longest and most
reproducible portion of the ventilatory cycle.
Ventilatory-gated therapy seems to spare more normal
structures such as the lung for patients with tumor volumes
100 cm3 (usually 5 cm in diameter if the tumor is almost
round) and tumor motion of more than 1 cm. In general,
tumors in the lower lobes of the lung move more than those
in other locations during breathing. An optimal margin with
gated treatment is dependent on patient breath regularity and
the technique used. A 5-mmmargin is suggested to allow for the
uncertainty of day-to-day tumor localization from gating.40
Motion Tracking Approach
The motion tracking approach is described in the on-
board image and real-time tracking sections.
IMAGE-GUIDED RADIATION DELIVERY AND
ADAPTED RADIOTHERAPY
On-Board Imaging Techniques
Electronic 2-D Projection Radiographs
Two-dimensional (2-D) radiographic imaging such as
with the megavoltage (MV) electronic portal imaging device
(EPID) is typically used in treatment rooms to align and
verify the patient treatment position and the shape of the
treatment portals. Disadvantages of pretreatment MV imag-
ing include the high imaging dose (typically 1–5 cGy) and
poor image quality due to the high X-ray beam energies.
Recently, on-board imagers using a kilovoltage (kV) X-ray
tube combined with a flat panel image detector mounted orthog-
onally to the therapy X-ray beam on a linear accelerator were
developed to set up the patient and verify the position. With its
superior image quality for visualizing bony structures and its low
imaging dose, in-room kV X-ray imaging represents a major
upgrade from the traditional EPID.
On-Board CT on Rails
3-D “volumetric” imaging inside a treatment room repre-
sents the latest development in IGRT. CT images provide
FIGURE 3. On-board images and adapted
radiotherapy. A, kV cone-beam CT (Varian Tril-
ogy). B, CT on rails. C, Adapted radiotherapy
based on three-dimensional images using on-
board CT. The patient was aligned based on a
bony landmark. The target coverage was veri-
fied in daily CT images using the simulation CT
images as reference. Appropriate adjustments
were made before each treatment.
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complete volumetric and anatomic information in the treatment
room coordinates. The in-room CT image can then be aligned
with the reference CT acquired for planning purposes before the
start of the treatment course (Figure 3). Such alignment is based
on soft-tissue and bony contrast. More importantly, in-room CT
images can be used to reconstruct dose distributions based on the
anatomy captured just before treatment. They allow image-
guided adaptive radiotherapy by modifying treatment parame-
ters according to changes in the patient’s anatomy before each
treatment or during the course of radiotherapy (Figure 3).
On-Board MV or KV Cone-Beam CT
MV cone-beam CT (MVCBCT) uses EPID mounted on
a Linac gantry and the therapy megavoltage X-ray as the
basic configuration for a CT imaging system. Kilovoltage cone-
beamCT (kVCBCT) imaging produces multiple kV radiographs
as the gantry rotates. Because of the use of low-kV X-ray
energy, kVCBCT images provide better soft-tissue contrast
compared with MVCBCT, which can be used for soft tissue
target delineation. Integration of this technology with a medical
accelerator, such as the Varian Trilogy (Figure 3) or Elekta
Synergy unit, provides an excellent platform for high-precision,
image-guided radiation therapy.
Tomotherapy
Tomotherapy (TomoTherapy Inc., Madison, WI) is an
integrated technology that combines a helical megavoltage
CT (MVCT) with a linear accelerator that is specifically
designed for delivering intensity-modulated radiation in a slit
geometry (Figure 4). Helical tomotherapy refers to the con-
tinuous gantry and couch motion during radiotherapy deliv-
ery, which resembles the motion from a conventional helical
CT scanner. Low-dose (typically 1–2 cGy) pretreatment
MVCT images can be reconstructed from the same MV X-ray
beam used for treatment, and radiotherapy doses on the basis
of these images can be recalculated. Clinical experience
indicates that the image quality could be sufficient for delin-
eating anatomic structures, including the lungs, and adapted
radiotherapy based on MVCT images is possible.41–43
Real-Time Tracking
The main goal of real-time tracking is to minimize the
effect of target motion not only between treatments but also
during a treatment fraction. Real-time tracking usually re-
quires the shortest time delay between the detection of motion
to the execution of the correction. In almost all cases, surro-
gate markers such as fiducial markers or a subset of target
positional information is used.
The Novalis Body System (BrainLAB AG, Heimstet-
ten, Germany, Figure 5A) is an integrated IGRT system for
target localization, setup correction, and the delivery of high-
precision stereotactic radiosurgery to monitor the movement
of infrared-reflecting markers placed on the patient’s skin and
to perform further internal target alignment based on either
bony landmarks or implanted fiducial markers. Two types of
treatment interventions can be performed: adaptive gating of
the treatment beam or real-time correction of target offset by
using a robotic couch.44,45
FIGURE 4. Tomotherapy is an integrated IGRT system com-
bining a linear accelerator with an MVCT image guidance
system.
FIGURE 5. Real-time tracking radiation therapy (RTRT). A,
BrainLAB. B, CyberKnife system.
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The CyberKnife system (Accuracy Inc., Sunnyvale, CA,
Figure 5B) is a room-mounted X-ray stereoscopic guidance
system designed primarily for radiosurgery applications. The
CyberKnife system is essentially an intelligent robotic applica-
tion in radiotherapy. The radiation source is a small X-band
linear accelerator mounted on a robotic arm. A ceiling-mounted
stereoscopic X-ray imaging system is used for patient setup and
for tracking of target movement during treatment. The robotic
arm can move at a speed of several centimeters per second,
which allows it to keep up with tumor motion because of
breathing. The CyberKnife was the first clinical radiotherapy
system to use real-time motion compensation and has been
shown to track tumor motion in lung cancer.46–48
Rationale and Potential Benefit of IGRT
With the availability of 4-D CT-based radiotherapy
planning and on-board imaging, accurate positioning of the
target volume using daily image guidance may result in less
chance of target miss, smaller set-up margins, and less normal
tissue exposed to high radiation doses. Novel treatment plan
adaptation algorithms may provide more effective modifica-
tion of treatment plans to adapt to the changes in a patient’s
anatomy and organ motion during and/or between (intra-
and/or inter-) treatment fractions.
The dosimetric consequence of intrafractional breathing
motion in lung tumors can be demonstrated by using 4D CT
images. In Figure 6, we show a case of mobile lung cancer in
which a free-breathing CT image was used to design a treatment
plan with an 8-mm margin to cover the CTV, as is the common
practice in the absence of 4-D CT. The dose distribution for each
breathing phase was calculated using the 4D CT data set. The
actual dose distribution did not cover the entire target volume in
some of the breathing phases because of respiratory motion,
which may not be detected using free-breathing CT. We also
calculated the cumulative dose distribution when using the
internal target volume (ITV), determined from the full range of
motion for the target in all 10 phases of the 4-D CT, for
treatment planning. The use of ITV-based 4-D CT planning
provided adequate coverage for all 10 phases. This example
illustrates the importance of quantifying patient-specific organ
motion in treatment planning so that adequate treatment margins
can be obtained.
Interfraction tumor motion and anatomy changes dur-
ing the course of radiotherapy are also a major cause of
missing the target and/or over-treating normal tissues in lung
cancer. In one study, weekly 4-D CT images were used to
investigate the magnitude of the changes in mobility and
tumor volume in NSCLC during 7 weeks of radiotherapy.36
Tumor volume reduction was found to range from 20 to 71%
and significant increased tumor mobility was observed, par-
ticularly in the superior–inferior and anterior–posterior direc-
tions. In some cases, an explicit initial determination of the
ITV may not be sufficient to cover the target owing to variations
in tumor motion and anatomy during the course of radiotherapy.
Repeat 4D CT imaging might be warranted for highly mobile
tumors to reduce the potential for missing the tumor.
It remains unclear if we should reduce the target vol-
ume if the gross tumor shrinks during the course of radio-
therapy.36,41–43 The concern about potential residual micro-
scopic disease after gross tumor shrinkage makes some
physicians believe that the target volume should not be reduced.
One option is to deliver at least 50 Gy, the standard dose for
microscopic disease, to the original target volume and then boost
the current visible lesion to the full dose. Clinical studies ad-
dressing these issues of inter- and intrafractional variations are
still scarce, and well-designed clinical studies are needed.
Image-Guided Stereotactic Body Radiotherapy
The conventional radiotherapy dose (60–66 Gy) for
patients with early-stage NSCLC is associated with a local
recurrence rate of more than 50%. Phase II clinical studies
have shown that hypofractionated SBRT provides promising
FIGURE 6. Example of missing the target because of intrafraction tumor motion. An IMRT plan was developed for a stage I
NSCLC located in the left lower lobe using conventional free-breath CT simulation with uniform PTV margin. The plan was
recalculated in 10 breathing phases obtained using 4-D CT. The inferior portion of the CTV (yellow line) moved outside the
prescription dose line (red line, 70 Gy) in phases 1 through 4.
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local control rates (85%) and survival rates with minimal
toxicity in patients with stage I (T1–2 N0 M0) or select stage
II (T3 N0 M0) NSCLC because of higher biologically effec-
tive dose (BEDs) and more accurate targeting.5–9 According
to Onishi et al.,6 BEDs of 100 Gy (using / of 10) or more
are associated with better local control (91.9 vs. 73.6%) and
survival rates (88.4 vs. 69.4%) than are BEDs of 100 Gy.
However, the optimal dose regimen for SBRT is controver-
sial. Peripheral lesions can be subjected to higher BEDs, such
as 60 Gy in three fractions developed by Dr. Timmerman’
group (current RTOG phase II clinical trial regimen), but
treatment of centrally located lesions with such a high-BED
regimen can be associated with considerable long-term tox-
icity.49 Because of the significantly higher fraction size used
in SBRT, IGRT is crucial for optimal target coverage and
sparing of normal structures.
Recently, a phase II clinical trial was conducted at
M. D. Anderson Cancer Center in 113 patients with pe-
ripherally or centrally located, medically inoperable stage
I or isolated recurrent NSCLC8 who underwent 4-D CT-
based planning and daily CT-on-rails-guided SBRT (Fig-
ure 3B, C, see “On-Board CT on Rails” section for tech-
nique details). The prescribed dose was 50 Gy to the PTV
delivered in 4 consecutive days. Dosing to the major
mediastinal critical organs was restricted to 35 to 40 Gy
delivered to 10 mL, except for the esophagus, for which
dosing was restricted to no more than 1 mL at 40 Gy. Daily
3-D image analysis showed that daily shifts (mean, 0.2 
0.6 cm; range, 0 –3.1 cm) from the external skin marks to
the final treatment position were required. Statistically
significant interfractional GTV shifts relative to the bone
happened in 30% of cases, and 10% of cases had more than
5-mm systematic changes. Daily CT on rails provides the
advantages of 3-D bony alignment and soft-tissue GTV
visibility to guide the decision regarding the final treat-
ment position. The overall progression-free (at the treated
site, which included centrally located lesions) survival rate
was 95.9%, with minimal toxicity (median follow-up: 12
months). Long-term follow-up is needed to confirm the
results.
Image-Guided Intensity-Modulated Radiation
Therapy to Take Tumor Motion into
Consideration
The use of IMRT for lung cancer has been delayed
because of concerns that it may deliver low, yet damaging,
doses to larger volumes of normal lung tissue than does
conventional 3-D CRT. Moreover, tumor movement due to
respiration introduces another level of complexity to both the
IMRT dosimetry and the technique used.
Virtual clinical studies were conducted to compare
IMRT with 3-D CRT with respect to target dose, tumor
conformity, and normal tissue sparing in patients with early-
stage and locally advanced NSCLC.50,51 IMRT may be more
suitable than 3-D CRT treatment planning for patients with
advanced-stage disease with large GTVs and thus greater
volumes of normal lung exposed to irradiation. Using IMRT,
the median absolute reduction in the percentage of lung
volume irradiated to more than 10 Gy was 7% and that
irradiated to more than 20 Gy was 10%. The volumes of the
heart and esophagus irradiated to about 50 Gy and the volume
of normal thoracic tissue irradiated to more than 10 to 40 Gy
were also reduced using the IMRT plans. A marginal increase
was noted in the lung volume exposed to more than 5 Gy
(V5) in the IMRT plans in half of the patients. V5 was found
to be correlated with lung toxicity (see next section and Table
1 for V5 dose constraints). To reduce the potential for
delivering low doses (10 Gy) to normal lung and to reduce
beam delivery time, the use of fewer beam (5–7 beams) is
suggested.11
Although IMRT may be effective in reducing normal
tissue toxicity and improving tumor coverage, its high
dose gradient and conformity require high levels of preci-
sion in dose delivery and tumor localization. The complex-
ity introduced by tumor motion must also be recognized
when using IMRT,52 and 4-D CT planning is recom-
mended. Unlike 3-D CRT, IMRT treats only a portion of
the target volume at a particular time. A great deal of
concern has been expressed as to whether target motion
and collimator motion during IMRT delivery have substan-
tial interplay, thus degrading the planned dose distribu-
tions. For IMRT to be feasible and more effective in
treating NSCLC, motion-reduction techniques such as
breath-holding and tumor tracking should be explored
further. Preliminary clinical studies indicate that IMRT
may reduce toxic effects in normal tissue in selected
patients, particularly for those with tumors that movement
can be controlled to be 5 mm, such as in the case of a
superior sulcus tumor with chest wall/vertebral body in-
volvement, and may allow further dose escalation.10 We
recently developed IMRT guidelines for treating NSCLC
using IGRT11 and the detail techniques have be described
in recently published book, IGRT in lung cancer.53 A
phase III clinical study to compare image-guided IMRT
with 3-D CRT in stage III NSCLC is ongoing.
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